Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

31 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Ceftolozane/tazobactam for the treatment of multidrug resistant Pseudomonas aeruginosa: experience from the Balearic Islands.
Díaz-Cañestro M, Periañez L, Mulet X, Martin-Pena ML, Fraile-Ribot PA, Ayestarán I, Colomar A, Nuñez B, Maciá M, Novo A, Torres V, Asensio J, López-Causapé C, Delgado O, Pérez JL, Murillas J, Riera M, Oliver A. Díaz-Cañestro M, et al. Eur J Clin Microbiol Infect Dis. 2018 Nov;37(11):2191-2200. doi: 10.1007/s10096-018-3361-0. Epub 2018 Aug 23. Eur J Clin Microbiol Infect Dis. 2018. PMID: 30141088
In Vivo Emergence of Resistance to Novel Cephalosporin-β-Lactamase Inhibitor Combinations through the Duplication of Amino Acid D149 from OXA-2 β-Lactamase (OXA-539) in Sequence Type 235 Pseudomonas aeruginosa.
Fraile-Ribot PA, Mulet X, Cabot G, Del Barrio-Tofiño E, Juan C, Pérez JL, Oliver A. Fraile-Ribot PA, et al. Antimicrob Agents Chemother. 2017 Aug 24;61(9):e01117-17. doi: 10.1128/AAC.01117-17. Print 2017 Sep. Antimicrob Agents Chemother. 2017. PMID: 28674059 Free PMC article.
Characterization of AmpC β-lactamase mutations of extensively drug-resistant Pseudomonas aeruginosa isolates that develop resistance to ceftolozane/tazobactam during therapy.
Fernández-Esgueva M, López-Calleja AI, Mulet X, Fraile-Ribot PA, Cabot G, Huarte R, Rezusta A, Oliver A. Fernández-Esgueva M, et al. Enferm Infecc Microbiol Clin (Engl Ed). 2020 Dec;38(10):474-478. doi: 10.1016/j.eimc.2020.01.017. Epub 2020 Mar 3. Enferm Infecc Microbiol Clin (Engl Ed). 2020. PMID: 32143893 English, Spanish.
Molecular and biochemical insights into the in vivo evolution of AmpC-mediated resistance to ceftolozane/tazobactam during treatment of an MDR Pseudomonas aeruginosa infection.
Arca-Suárez J, Vázquez-Ucha JC, Fraile-Ribot PA, Lence E, Cabot G, Martínez-Guitián M, Lasarte-Monterrubio C, Rodríguez-Iglesias M, Beceiro A, González-Bello C, Galán-Sánchez F, Oliver A, Bou G. Arca-Suárez J, et al. J Antimicrob Chemother. 2020 Nov 1;75(11):3209-3217. doi: 10.1093/jac/dkaa291. J Antimicrob Chemother. 2020. PMID: 32728723
Activity of cefiderocol, imipenem/relebactam, cefepime/taniborbactam and cefepime/zidebactam against ceftolozane/tazobactam- and ceftazidime/avibactam-resistant Pseudomonas aeruginosa.
Lasarte-Monterrubio C, Fraile-Ribot PA, Vázquez-Ucha JC, Cabot G, Guijarro-Sánchez P, Alonso-García I, Rumbo-Feal S, Galán-Sánchez F, Beceiro A, Arca-Suárez J, Oliver A, Bou G. Lasarte-Monterrubio C, et al. Among authors: fraile ribot pa. J Antimicrob Chemother. 2022 Sep 30;77(10):2809-2815. doi: 10.1093/jac/dkac241. J Antimicrob Chemother. 2022. PMID: 35904000
Challenging Antimicrobial Susceptibility and Evolution of Resistance (OXA-681) during Treatment of a Long-Term Nosocomial Infection Caused by a Pseudomonas aeruginosa ST175 Clone.
Arca-Suárez J, Fraile-Ribot P, Vázquez-Ucha JC, Cabot G, Martínez-Guitián M, Lence E, González-Bello C, Beceiro A, Rodríguez-Iglesias M, Galán-Sánchez F, Bou G, Oliver A. Arca-Suárez J, et al. Antimicrob Agents Chemother. 2019 Sep 23;63(10):e01110-19. doi: 10.1128/AAC.01110-19. Print 2019 Oct. Antimicrob Agents Chemother. 2019. PMID: 31383659 Free PMC article.
31 results